APOC3 and familial chylomicronemia syndrome: Volanesorsen, a type of medication that targets APOC3 mRNA using antisense oligonucleotides, has proven effective in reducing triglyceride levels in individuals with familial chylomicronemia syndrome, a rare genetic condition characterized by extremely high levels of triglycerides.